Association of CYP24A1 with survival and drug resistance in clinical cancer patients: a meta-analysis

Background: Acquired chemo-drug resistance constantly led to the failure of chemotherapy for malignant cancers, consequently causing cancer relapse. Hence, identifying the biomarker of drug resistance in cancer is vital to improve the treatment efficacy. The clinical prognostic value of CYP24A1 remains conclusive, we aim to evaluate the association between CYP24A1 and the drug resistance in cancer patients through a meta-analysis approach. Method: Relevant studies detecting the expression or SNP of CYP24A1 in cancer patients up till May 2022 were systematically searched in four common scientific databases including PubMed, EMBASE, Cochrane library and ISI Web of Science. The pooled hazard ratios (HRs) indicating the ratio of hazard rate of survival time between CYP24A1 high population vs CYP24A1 low population were calculated. The pooled HRs and odds ratios (ORs) with 95% confidence intervals (CIs) were used to explore the association between CYP24A1’s expression or SNP with survival, metastasis, recurrence, and drug resistance in cancer patients. Result: Fifteen studies were included in the meta-analysis after an initial screening according to the inclusion and exclusion criteria. There was a total of 3784 patients pooled from all the included studies. Results obtained indicated that high expression or SNP of CYP24A1 was significantly correlated with shorter survival time with pooled HRs (95% CI) of 1.21 (1.12, 1.31), metastasis with pooled ORs (95% CI) of 1.81 (1.11, 2.96), recurrence with pooled ORs (95% CI) of 2.14 (1.45, 3.18) and drug resistance with pooled HRs (95% CI) of 1.42 (1.17, 1.68). In the subgroup analysis, cancer type, treatment, and detection approach for CYP24A1 did not affect the significance of the association between CYP24A1 expression and poor prognosis. Conclusion: Findings from our meta-analysis demonstrated that CYP24A1’s expression or SNP was correlated with cancer progression and drug resistance. Therefore, CYP24A1 could potentially be used as a molecular marker for cancer resistance.